EVElise Valkanas

Elise Valkanas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elise Valkanas has a total of 170 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The landscape of gene loss and missense variation across the mammalian tree informs on gene essentiality

    by Calwing Liao, Robert Ye, Franjo Ivankovic, Jack M. Fu, Raymond Walters, Chelsea Lowther, Elise Valkanas, Claire Churchhouse, Kaitlin E. Samocha, Kerstin Lindblad-Toh, et al.

    Patterns of gene and sequence preservation across species provide insight into gene essentiality under natural selection. Here we developed two interspecies constraint metrics across 462 mammalian species: Gene Identity Score of Mammalian Orthologs (GISMO), which quantifies gene loss weighted by evolutionary distance to humans, and GISMO-mis, which measures missense constraint using the ratio of missense to synonymous variation across mammals. Both metrics are strongly correlated with human loss of function, missense and dosage constraint derived from large-scale sequencing studies, yet are largely independent of coding sequence length. GISMO and GISMO-mis identify essential genes missed by existing human-only metrics, particularly short genes. Genes in the most constrained deciles are enriched for rare variant associations in disorders linked to reduced fecundity, including schizophrenia, autism and neurodevelopmental disorders, and show strong enrichment for common variant heritability. These deciles also exhibit reduced copy number variation, consistent with dosage sensitivity. In addition, GISMO improves prioritization of recessive disease genes and captures signatures of homozygous selection across the mammalian tree. Taken together, GISMO and GISMO-mis leverage deep mammalian evolution to provide complementary, length-robust measures of gene essentiality that strengthen disease–gene prioritization and illuminate the selective forces shaping human biology.

  • Open Access

    Phylogeography and Population Genetics of the Kentucky Endemic Cave Beetle Genus Neaphaenops Jeannel (1920) (Coleoptera: Carabidae: Trechini)

    by Mahamad Sayab Miya, Elise Valkanas, T. Keith Philips

    Cave beetles are an excellent group for studying evolutionary history and speciation within cave habitats. However, they are underrepresented in such research, particularly in North America, a hotspot of cave biodiversity, where beetles account for a significant proportion of documented taxa. This study aims to elucidate the evolutionary history and possible connectivity or barriers to gene flow among populations of the central Kentucky endemic cave beetle, Neaphaenops tellkampfii (Erichson), and to test the validity of four proposed subspecies. We collected specimens from 62 caves, extracted DNA, and sequenced 1169 bp of the Cytochrome C Oxidase Subunit I (CO1) gene, resulting in 36 phylogenetically informative sites for the ingroup. Using this CO1 data, we constructed Bayesian, Maximum Likelihood, and Parsimony phylogenetic trees and also visualized the genetic structure. All the analyses illustrated two distinct southern and northern mega‐populations of this beetle, separated by the Barren River. Based on molecular evidence, here we propose a new concept that the four morphologically defined subspecies should be considered invalid. The three northern subspecies: N. t. tellkampfii (Erichson), N. t. viator Barr, and N. t. henroti Jeannel should be recognized as the single species N. tellkampfii (Erichson), while the southern subspecies N. t. meridionalis Barr should be raised to species level as N. meridionalis Barr, New Status. This study also discovered 26 new Neaphaenops populations. High genetic similarity was observed within each clade, potentially indicating a high level of historical or recent interconnectivity among the caves within the Mississippian Plateau that facilitates underground dispersal and gene flow. Together, our study shows that Neaphaenops or other cave beetles can serve as a biological model for studying speciation, gene flow, evolutionary history, and connectivity within cave systems.

  • Open Access

    Author Correction: A structural variation reference for medical and population genetics

    by Genome Aggregation Database Production Team, Ryan L. Collins, Genome Aggregation Database Consortium, Harrison Brand, Konrad J. Karczewski, Xuefang Zhao, Jessica Alföldi, Laurent C. Francioli, Amit V. Khera, Chelsea Lowther, et al.

    A Correction to this paper has been published: https://doi.org/10.1038/s41586-020-03176-6.


  • Open Access

    WGS and RNA Studies Diagnose Noncoding DMD Variants in Males With High Creatine Kinase

    by Leigh B. Waddell, Samantha J. Bryen, Beryl B. Cummings, Adam Bournazos, Frances J. Evesson, Himanshu Joshi, Jamie L. Marshall, Taru Tukiainen, Elise Valkanas, Ben Weisburd, et al.

    Objective To describe the diagnostic utility of whole-genome sequencing and RNA studies in boys with suspected dystrophinopathy, for whom multiplex ligation-dependent probe amplification and exomic parallel sequencing failed to yield a genetic diagnosis, and to use remnant normal DMD splicing in 3 families to define critical levels of wild-type dystrophin bridging clinical spectrums of Duchenne to myalgia. Methods Exome, genome, and/or muscle RNA sequencing was performed for 7 males with elevated creatine kinase. PCR of muscle-derived complementary DNA (cDNA) studied consequences for DMD premessenger RNA (pre-mRNA) splicing. Quantitative Western blot was used to determine levels of dystrophin, relative to control muscle. Results Splice-altering intronic single nucleotide variants or structural rearrangements in DMD were identified in all 7 families. Four individuals, with abnormal splicing causing a premature stop codon and nonsense-mediated decay, expressed remnant levels of normally spliced DMD mRNA. Quantitative Western blot enabled correlation of wild-type dystrophin and clinical severity, with 0%–5% dystrophin conferring a Duchenne phenotype, 10% ± 2% a Becker phenotype, and 15% ± 2% dystrophin associated with myalgia without manifesting weakness. Conclusions Whole-genome sequencing relied heavily on RNA studies to identify DMD splice-altering variants. Short-read RNA sequencing was regularly confounded by the effectiveness of nonsense-mediated mRNA decay and low read depth of the giant DMD mRNA. PCR of muscle cDNA provided a simple, yet informative approach. Highly relevant to genetic therapies for dystrophinopathies, our data align strongly with previous studies of mutant dystrophin in Becker muscular dystrophy, with the collective conclusion that a fractional increase in levels of normal dystrophin between 5% and 20% is clinically significant.


  • Top Cited Papers
    Open Access

    A structural variation reference for medical and population genetics

    by Ryan L. Collins, Harrison Brand, Konrad J. Karczewski, Xuefang Zhao, Jessica Alföldi, Laurent C. Francioli, Amit V. Khera, Chelsea Lowther, Laura D. Gauthier, Harold Wang, et al.

    Structural variants (SVs) rearrange large segments of DNA1 and can have profound consequences in evolution and human disease2,3. As national biobanks, disease-association studies, and clinical genetic testing have grown increasingly reliant on genome sequencing, population references such as the Genome Aggregation Database (gnomAD)4 have become integral in the interpretation of single-nucleotide variants (SNVs)5. However, there are no reference maps of SVs from high-coverage genome sequencing comparable to those for SNVs. Here we present a reference of sequence-resolved SVs constructed from 14,891 genomes across diverse global populations (54% non-European) in gnomAD. We discovered a rich and complex landscape of 433,371 SVs, from which we estimate that SVs are responsible for 25–29% of all rare protein-truncating events per genome. We found strong correlations between natural selection against damaging SNVs and rare SVs that disrupt or duplicate protein-coding sequence, which suggests that genes that are highly intolerant to loss-of-function are also sensitive to increased dosage6. We also uncovered modest selection against noncoding SVs in cis-regulatory elements, although selection against protein-truncating SVs was stronger than all noncoding effects. Finally, we identified very large (over one megabase), rare SVs in 3.9% of samples, and estimate that 0.13% of individuals may carry an SV that meets the existing criteria for clinically important incidental findings7. This SV resource is freely distributed via the gnomAD browser8 and will have broad utility in population genetics, disease-association studies, and diagnostic screening.


  • Open Access

    Detection of variants in dystroglycanopathy-associated genes through the application of targeted whole-exome sequencing analysis to a large cohort of patients with unexplained limb-girdle muscle weakness

    by Katherine Johnson, Marta Bertoli, Lauren Phillips, Ana Töpf, Peter Van Den Bergh, John Vissing, Nanna Witting, Shahriar Nafissi, Shirin Jamal-Omidi, Anna Łusakowska, et al.

    Dystroglycanopathies are a clinically and genetically heterogeneous group of disorders that are typically characterised by limb-girdle muscle weakness. Mutations in 18 different genes have been associated with dystroglycanopathies, the encoded proteins of which typically modulate the binding of α-dystroglycan to extracellular matrix ligands by altering its glycosylation. This results in a disruption of the structural integrity of the myocyte, ultimately leading to muscle degeneration. Deep phenotypic information was gathered using the PhenoTips online software for 1001 patients with unexplained limb-girdle muscle weakness from 43 different centres across 21 European and Middle Eastern countries. Whole-exome sequencing with at least 250 ng DNA was completed using an Illumina exome capture and a 38 Mb baited target. Genes known to be associated with dystroglycanopathies were analysed for disease-causing variants. Suspected pathogenic variants were detected in DPM3, ISPD, POMT1 and FKTN in one patient each, in POMK in two patients, in GMPPB in three patients, in FKRP in eight patients and in POMT2 in ten patients. This indicated a frequency of 2.7% for the disease group within the cohort of 1001 patients with unexplained limb-girdle muscle weakness. The phenotypes of the 27 patients were highly variable, yet with a fundamental presentation of proximal muscle weakness and elevated serum creatine kinase. Overall, we have identified 27 patients with suspected pathogenic variants in dystroglycanopathy-associated genes. We present evidence for the genetic and phenotypic diversity of the dystroglycanopathies as a disease group, while also highlighting the advantage of incorporating next-generation sequencing into the diagnostic pathway of rare diseases.


  • Open Access

    Contribution of non-coding mutations to RPGRIP1 -mediated inherited retinal degeneration

    by Farzad Jamshidi, Emily M. Place, Sudeep Mehrotra, Daniel Navarro-Gomez, Mathew Maher, Elise Valkanas, Timothy J. Cherry, Monkol Lek, Daniel MacArthur, Eric A. Pierce, et al.

    Purpose: With the advent of gene therapies for inherited retinal degenerations (IRDs), genetic diagnostics will have an increasing role in clinical decision-making. Yet the genetic cause of disease cannot be identified using exon-based sequencing for a significant portion of patients. We hypothesized that non-coding mutations contribute significantly to the genetic causality of IRDs and evaluated patients with single coding mutations in RPGRIP1 to test this hypothesis. Methods: IRD families underwent targeted panel sequencing. Unsolved cases were explored by whole exome and genome sequencing looking for additional mutations. Candidate mutations were then validated by Sanger sequencing, quantitative PCR, and in vitro splicing assays in two cell lines analyzed through amplicon sequencing. Results: Among 1722 families, three had biallelic loss of function mutations in RPGRIP1 while seven had a single disruptive coding mutation. Whole exome and genome sequencing revealed potential non-coding mutations in these seven families. In six, the non-coding mutations were shown to lead to loss of function in vitro . Conclusion: Non-coding mutations were identified in 6 of 7 families with single coding mutations in RPGRIP1 . The results suggest that non-coding mutations contribute significantly to the genetic causality of IRDs and RPGRIP1 –mediated IRDs are more common than previously thought.

  • Open Access

    Pharmacogenomic incidental findings in 308 families: The NIH Undiagnosed Diseases Program experience

    by Elizabeth M.J. Lee, Karen Xu, Emma Mosbrook, Amanda Links, Jessica Guzman, David R. Adams, Elise Flynn, Elise Valkanas, Camillo Toro, Cynthia J. Tifft, et al.


  • Open Access

    Computational evaluation of exome sequence data using human and model organism phenotypes improves diagnostic efficiency

    by William P. Bone, Nicole L. Washington, Orion J. Buske, David R. Adams, Joie Davis, David Draper, Elise D. Flynn, Marta Girdea, Rena Godfrey, Gretchen Golas, et al.